Lasa Supergenerics (NSE:LASA, BOM:540702) expanded its production capacity for Albendazole USP through debottlenecking of existing infrastructure and installing new machinery at the unit, according to a Thursday bourse filing.
The veterinary API manufacturer invested around 10 million Indian rupees in the expansion, which will help meet the demand for Albendazole across domestic and international markets.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.